Ignite Creation Date:
2024-05-06 @ 9:08 AM
Last Modification Date:
2024-10-26 @ 12:10 PM
Study NCT ID:
NCT02911844
Status:
COMPLETED
Last Update Posted:
2019-12-09
First Post:
2016-09-19
Brief Title:
Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ERA-PAH
Brief Summary:
The main purpose of this clinical trial is to examine the feasibility and effects of fulvestrant in post-menopausal women with pulmonary arterial hypertension PAH The study will evaluate how well the drug is tolerated The study will evaluate changes in circulating hematopoietic progenitor cells plasma hormone levels NT-proBNP and other plasma biomarkers after the administration of fulvestrant Changes in tricuspid annular plane systolic excursion stroke volume index right ventricular fractional area change and other echo parameters after fulvestrant administration will be evaluated as well as changes in distance walked in six minutes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None